675 results
Search Results
2. Liposomes, transfersomes and niosomes: production methods and their applications in the vaccinal field.
- Author
-
Riccardi, Domenico, Baldino, Lucia, and Reverchon, Ernesto
- Subjects
SUPERCRITICAL carbon dioxide ,PRODUCTION methods ,LIPOSOMES ,DNA vaccines - Abstract
One of the most effective strategies to fight viruses and handle health diseases is vaccination. Recent studies and current applications are moving on antigen, DNA and RNA-based vaccines to overcome the limitations related to the conventional vaccination strategies, such as low safety, necessity of multiple injection, and side effects. However, due to the instability of pristine antigen, RNA and DNA molecules, the use of nanocarriers is required. Among the different nanocarriers proposed for vaccinal applications, three types of nanovesicles were selected and analysed in this review: liposomes, transfersomes and niosomes. PubMed, Scopus and Google Scholar databases were used for searching recent papers on the most frequently used conventional and innovative methods of production of these nanovesicles. Weaknesses and limitations of conventional methods (i.e., multiple post-processing, solvent residue, batch-mode processes) can be overcome using innovative methods, in particular, the ones assisted by supercritical carbon dioxide. SuperSomes process emerged as a promising production technique of solvent-free nanovesicles, since it can be easily scaled-up, works in continuous-mode, and does not require further post-processing steps to obtain the desired products. As a result of the literature analysis, supercritical carbon dioxide assisted methods attracted a lot of interest for nanovesicles production in the vaccinal field. However, despite their numerous advantages, supercritical processes require further studies for the production of liposomes, transfersomes and niosomes with the aim of reaching well-defined technologies suitable for industrial applications and mass production of vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. REVIEW OF QUALITY CONTROL APPROACHES FOR BIOTECHNOLOGY-DERIVED VACCINES.
- Author
-
Alshahrani, Salem Mohammed
- Subjects
QUALITY control ,COVID-19 vaccines ,VACCINES ,VACCINE effectiveness ,IMMUNE response - Abstract
This paper aimed to systematically review the quality control approaches for biotechnology-derived vaccines, including the covid vaccines. Google Scholar was used for selecting papers, which was limited to 28 to ensure that the review is not too long. From the 28 papers, 14 were reviews. There were only four research papers, of which, two were on covid vaccines. Thus, the diversity of the available quality control approaches was already limited. Many quality control tests are performed through the entire chain of sourcing to the end-user. Safety, purity, product integrity, efficacy, immunogenicity, and absence of side effects were the important quality control variables identified as critical for the effective use of vaccines, in most studies. This observation applies to covid vaccines also. As a self-check of the quality of the vaccine by the manufacturer may not be accepted by others, it is desirable to cross-check the reliability and validity of the factory quality test results through third-party testing. Often, despite all quality parameters being satisfactory, the vaccines fail in actual use. There could be a difference between the laboratory results and the real-world experiences of covid vaccines. The factors leading to this problem are not yet clear. International guidelines and standards help to ensure uniform quality of vaccines across the world facilitating the use of the same vaccines in different countries. This is evident from the covid vaccine exports from leading producer countries to other parts of the world. The essentiality of ensuring the proper quality of all vaccines, including covid vaccines, is clear from this review. The future is for the possibility of rapid quality tests facilitated by multiplex testing tools, non-animal testing, the use of plantbased vaccines aided by molecular farming, and larger-scale field evaluations of vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. In-depth review of delivery carriers associated with vaccine adjuvants: current status and future perspectives.
- Author
-
Zeng, Yarong, Zou, Feihong, Xia, Ningshao, and Li, Shaowei
- Subjects
VACCINES ,VACCINE development ,VACCINE effectiveness ,IMMUNE response - Abstract
Vaccines are powerful tools for controlling microbial infections and preventing epidemics. To enhance the immune response to antigens, effective subunit vaccines or mRNA vaccines often require the combination of adjuvants or delivery carriers. In recent years, with the rapid development of immune mechanism research and nanotechnology, various studies based on the optimization of traditional adjuvants or various novel carriers have been intensified, and the construction of vaccine adjuvant delivery systems (VADS) with both adjuvant activity and antigen delivery has become more and more important in vaccine research. This paper reviews the common types of vaccine adjuvant delivery carriers, classifies the VADS according to their basic carrier types, introduces the current research status and future development trend, and emphasizes the important role of VADS in novel vaccine research. As the number of vaccine types increases, conventional aluminum adjuvants show limitations in effectively stimulating cellular immune responses, limiting their use in therapeutic vaccines for intracellular infections or tumors. In contrast, the use of conventional adjuvants as VADS to carry immunostimulatory molecules or deliver antigens can greatly enhance the immune boosting effect of classical adjuvants. A comprehensive understanding of the various delivery vehicles will further facilitate the development of vaccine adjuvant research. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Canadian Adjuvant Initiative Workshop, March 26-27, 2013-Ottawa, Canada
- Author
-
Susan M. Twine, Luis Barreto, Lakshmi Krishnan, James C. Richards, and Volker Gerdts
- Subjects
health care delivery ,medicine.medical_treatment ,Alternative medicine ,experimental model ,vaccine production ,Meeting Report ,immunogenicity ,immune response ,drug approval ,Neoplasms ,Immunology and Allergy ,Medicine ,CD8+ T lymphocyte ,conference paper ,commercial phenomena ,Public relations ,vaccines ,3. Good health ,health care policy ,Vaccines, Subunit ,Immunotherapy ,Adjuvant ,medicine.medical_specialty ,Canada ,Immunology ,education ,drug industry ,Unmet needs ,Education ,Adjuvants, Immunologic ,Humans ,Subunit vaccines ,veterinary vaccines ,Pharmacology ,Government ,business.industry ,bioprocessing ,Vaccine trial ,drug legislation ,bioprocess ,vaccination ,vaccine delivery systems ,drug formulation ,Chronic disease ,veterinary medicine ,regulatory approval ,Research council ,adjuvants ,Chronic Disease ,Immunization ,business ,Wart virus vaccine - Abstract
Novel adjuvants hold the promise for developing effective modern subunit vaccines capable of appropriately modulating the immune response against challenging diseases such as those caused by chronic and/or intracellular pathogens and cancer. Over the past decade there has been intensive research into discovering new adjuvants, however, their translation into routine clinical use is lagging. To stimulate discussion and identify opportunities for networking and collaboration among various stakeholders, a Canadian Adjuvant Initiative Workshop was held in Ottawa. Sponsored by the National Research Council Canada, Canadian Institutes of Health Research and the Vaccine Industry Committee, a two day workshop was held that brought together key Canadian and international stakeholders in adjuvant research from industry, academia and government. To discover innovation gaps and unmet needs, the presentations covered a board range of topics in adjuvant development; criteria for selection of lead adjuvant candidates from an industry perspective, discovery research across Canada, bioprocessing needs and challenges, veterinary vaccines, Canadian vaccine trial capabilities, the Canadian regulatory framework and WHO formulation laboratory experience. The workshop concluded with a discussion on the opportunity to create a Canadian Adjuvant Development Network. This report details the key discussion points and steps forward identified for facilitating adjuvant development research in Canada. © 2014 Landes Bioscience.
- Published
- 2014
6. Correlates of protection for meningococcal surface protein vaccines: current approaches for the determination of breadth of coverage.
- Author
-
Findlow, Jamie, Borrow, Ray, Stephens, David S., Liberator, Paul, Anderson, Annaliesa S., Balmer, Paul, and Jodar, Luis
- Subjects
NEISSERIA ,VACCINES ,PROTEIN expression ,PROTEINS ,AMINO acid sequence ,IMMUNE response - Abstract
The two currently licensed surface protein non-capsular meningococcal serogroup B (MenB) vaccines both have the purpose of providing broad coverage against diverse MenB strains. However, the different antigen compositions and approaches used to assess breadth of coverage currently make direct comparisons complex. In the second of two companion papers, we comprehensively review the serology and factors influencing breadth of coverage assessments for two currently licensed MenB vaccines. Surface protein MenB vaccines were developed using different approaches, resulting in unique formulations and thus their breadth of coverage. The surface proteins used as vaccine antigens can vary among meningococcal strains due to gene presence/absence, sequence diversity, and differences in protein expression. Assessment of the breadth of coverage provided by vaccines is influenced by the ability to induce cross-reactive functional immune responses to sequence diverse protein variants; the characteristics of the circulating invasive strains from specific geographic locations; methodological differences in the immunogenicity assays; differences in human immune responses between individuals; and the maintenance of protective antibody levels over time. Understanding the proportion of meningococcal strains, which are covered by the two licensed vaccines, is important in understanding protection from disease and public health use. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. Nonclinical testing of vaccines: Report from a workshop
- Author
-
Roy Forster, Sarah Gould, Lawrence Segal, Brian J. Ledwith, Andrée Penninks, Marion Gruber, Jan Willem van der Laan, and TNO Kwaliteit van Leven
- Subjects
reproductive toxicity ,drug safety ,workshop ,immunogenicity ,drug research ,immune response ,male fertility ,tattooing ,live vaccine ,vaccine ,Medicine ,Pharmacology (medical) ,conference paper ,Vaccines ,Attenuated vaccine ,drug dose regimen ,Developmental and reproductive toxicology ,Vaccination ,priority journal ,Preclinical testing ,Health ,Engineering ethics ,Immunomodulating Agent ,medicine.drug ,toxicology ,Vaccine research ,DNA vaccine ,electroporation ,Meningococcus vaccine ,Pharmacology (nursing) ,Context (language use) ,Pharmacy ,DNA vaccines ,diphtheria pertussis tetanus vaccine ,toxicity testing ,Drug Guides ,pharmacodynamics ,Adjuvants ,drug screening ,human ,nonhuman ,pertussis vaccine ,business.industry ,disease model ,practice guideline ,Public Health, Environmental and Occupational Health ,vaccination ,immunological adjuvant ,drug efficacy ,Nonclinical evaluation ,Safety testing ,Immunology ,Pertussis vaccine ,immunomodulating agent ,Therapeutic vaccines ,business ,Wart virus vaccine ,drug tolerability - Abstract
Vaccine research and development is a heterogeneous and intensely active area, encompassing the development of many different kinds of novel preventive and therapeutic vaccines (eg, against infectious, allergic, and autoimmune diseases, cancer, etc). Included in this is the development of different types of vaccines (eg, DNA vaccines, novel routes of administration, novel adjuvants, and immune system modulation). This poses challenges regarding approaches to preclinical evaluation of these products. Published regulatory guidance has not always kept up with scientific advances and innovation in this area and, at the same time, many vaccine developers are interested in better understanding and meeting regulatory expectations. It was in this context that in June 2007 a workshop was organized and held in Amsterdam (DIA International Workshop on Nonclinical Testing of Vaccines) to discuss the nonclinical aspects of vaccine development. This article provides a short historical overview of preclinical testing of vaccines and reviews and summarizes the discussions held during the June 2007 meeting. Copyright © 2009 Drug Information Association, Inc.
- Published
- 2009
8. Nonclinical testing of vaccines: Report from a workshop
- Subjects
DNA vaccine ,electroporation ,reproductive toxicity ,drug safety ,workshop ,Meningococcus vaccine ,immunogenicity ,drug research ,immune response ,male fertility ,DNA vaccines ,diphtheria pertussis tetanus vaccine ,tattooing ,live vaccine ,toxicity testing ,vaccine ,pharmacodynamics ,Adjuvants ,drug screening ,human ,conference paper ,Vaccines ,nonhuman ,pertussis vaccine ,drug dose regimen ,disease model ,practice guideline ,Developmental and reproductive toxicology ,vaccination ,immunological adjuvant ,drug efficacy ,Nonclinical evaluation ,priority journal ,Health ,Safety testing ,immunomodulating agent ,Therapeutic vaccines ,Wart virus vaccine ,drug tolerability ,toxicology - Abstract
Vaccine research and development is a heterogeneous and intensely active area, encompassing the development of many different kinds of novel preventive and therapeutic vaccines (eg, against infectious, allergic, and autoimmune diseases, cancer, etc). Included in this is the development of different types of vaccines (eg, DNA vaccines, novel routes of administration, novel adjuvants, and immune system modulation). This poses challenges regarding approaches to preclinical evaluation of these products. Published regulatory guidance has not always kept up with scientific advances and innovation in this area and, at the same time, many vaccine developers are interested in better understanding and meeting regulatory expectations. It was in this context that in June 2007 a workshop was organized and held in Amsterdam (DIA International Workshop on Nonclinical Testing of Vaccines) to discuss the nonclinical aspects of vaccine development. This article provides a short historical overview of preclinical testing of vaccines and reviews and summarizes the discussions held during the June 2007 meeting. Copyright © 2009 Drug Information Association, Inc.
- Published
- 2009
9. Early trail of CanSinoBIO's inhaled COVID-19 vaccine candidate indicates triggering of immune response
- Subjects
Immune response ,Vaccines ,Business ,Ad5-nCoV (Vaccine) - Abstract
M2 EQUITYBITES-July 28, 2021-Early trail of CanSinoBIO's inhaled COVID-19 vaccine candidate indicates triggering of immune response (C)2021 M2 COMMUNICATIONS http://www.m2.com An early stage clinical trial has indicated that an inhaled [...]
- Published
- 2021
10. Early trail of CanSinoBIO's inhaled COVID-19 vaccine candidate indicates triggering of immune response
- Subjects
Immune response ,Vaccines ,Chemistry ,Ad5-nCoV (Vaccine) - Abstract
M2 PHARMA-July 28, 2021-Early trail of CanSinoBIO's inhaled COVID-19 vaccine candidate indicates triggering of immune response (C)2021 M2 COMMUNICATIONS An early stage clinical trial has indicated that an inhaled version [...]
- Published
- 2021
11. A probabilistic model of pre-erythrocytic malaria vaccine combination in mice.
- Author
-
Atcheson, Erwan, Bauza, Karolis, and Reyes-Sandoval, Arturo
- Subjects
MALARIA vaccines ,COMMUNICABLE diseases ,VACCINE effectiveness ,IMMUNE response ,MEDICAL decision making - Abstract
Malaria remains one the world’s most deadly infectious diseases, with almost half a million deaths and over 150 million clinical cases each year. An effective vaccine would contribute enormously to malaria control and will almost certainly be required for eventual eradication of the disease. However, the leading malaria vaccine candidate, RTS,S, shows only 30–50% efficacy under field conditions, making it less cost-effective than long-lasting insecticide treated bed nets. Other subunit malaria vaccine candidates, including TRAP-based vaccines, show no better protective efficacy. This has led to increased interest in combining subunit malaria vaccines as a means of enhancing protective efficacy. Mathematical models of the effect of combining such vaccines on protective efficacy can help inform optimal vaccine strategies and decision-making at all stages of the clinical process. So far, however, no such model has been developed for pre-clinical murine studies, the stage at which all candidate antigens and combinations begin evaluation. To address this gap, this paper develops a mathematical model of vaccine combination adapted to murine malaria studies. The model is based on simple probabilistic assumptions which put the model on a firmer theoretical footing than previous clinical models, which rather than deriving a relationship between immune responses and protective efficacy posit the relationship to be either exponential or Hill curves. Data from pre-clinical murine malaria studies are used to derive values for unknowns in the model which in turn allows simulations of vaccine combination efficacy and suggests optimal strategies to pursue. Finally, the ability of the model to shed light on fundamental biological variables of murine malaria such as the blood stage growth rate and sporozoite infectivity is explored. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
12. SINOVAC advertises positive data for the CoronaVac(r) Booster Shots, strong adult and the elderly immune responses
- Subjects
Sinovac Biotech Ltd. ,Biological products industry ,Medical research ,Medicine, Experimental ,Advertising ,Immune response ,Adults ,Vaccines ,General interest ,News, opinion and commentary - Abstract
BEIJING: SINOVAC Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today the publication of two papers. The publications detail findings from clinical studies on the immunogenicity, safety, [...]
- Published
- 2021
13. Maternal nutritional status during pregnancy and infant immune response to routine childhood vaccinations.
- Author
-
Obanewa, Olayinka and Newell, Marie-Louise
- Abstract
To systematically review the association between maternal nutritional status in pregnancy and infant immune response to childhood vaccines. We reviewed literature on maternal nutrition during pregnancy, fetal immune system and vaccines and possible relationships. Thereafter, we undertook a systematic review of the literature of maternal nutritional status and infant vaccine response, extracted relevant information, assessed quality of the nine papers identified and present findings in a narrative format. From limited evidence of average quality, intrauterine nutrition deficiency could lead to functional deficit in the infant's immune function; child vaccine response may thus be negatively affected by maternal malnutrition. Response to childhood vaccination may be associated with fetal and early life environment; evaluation of programs should take this into account. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
14. New mRNA cancer vaccine triggers fierce immune response to fight malignant brain tumor
- Subjects
Cancer patients ,Immune response ,Gliomas ,Messenger RNA ,Brain tumors ,Medical colleges ,Vaccines ,Pets ,Business ,Health ,Health care industry ,University of Florida - Abstract
2024 MAY 19 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- In a first-ever human clinical trial of four adult patients, [...]
- Published
- 2024
15. Specific targeting of IL-1β activity to CD8+ T cells allows for safe use as a vaccine adjuvant.
- Author
-
Van Den Eeckhout, Bram, Van Hoecke, Lien, Burg, Elianne, Van Lint, Sandra, Peelman, Frank, Kley, Niko, Uzé, Gilles, Saelens, Xavier, Tavernier, Jan, and Gerlo, Sarah
- Subjects
T cells ,VACCINES ,IMMUNE response ,INTERLEUKIN-1 ,ANTIVIRAL agents - Abstract
Annual administration and reformulation of influenza vaccines is required for protection against seasonal infections. However, the induction of strong and long-lasting T cells is critical to reach broad and potentially lifelong antiviral immunity. The NLRP3 inflammasome and its product interleukin-1β (IL-1β) are pivotal mediators of cellular immune responses to influenza, yet, overactivation of these systems leads to side effects, which hamper clinical applications. Here, we present a bypass around these toxicities by targeting the activity of IL-1β to CD8
+ T cells. Using this approach, we demonstrate safe inclusion of IL-1β as an adjuvant in vaccination strategies, leading to full protection of mice against a high influenza virus challenge dose by raising potent T cell responses. In conclusion, this paper proposes a class of IL-1β-based vaccine adjuvants and also provides further insight in the mechanics of cellular immune responses driven by IL-1β. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
16. Towards new TB vaccines.
- Author
-
Brazier, Benedict and McShane, Helen
- Subjects
MYCOBACTERIUM tuberculosis ,VACCINES ,TUBERCULOSIS ,IMMUNE response ,CAUSES of death - Abstract
Mycobacterium tuberculosis remains the leading cause of death attributed to a single infectious organism. Bacillus Calmette-Guerin (BCG), the standard vaccine against M. tuberculosis, is thought to prevent only 5% of all vaccine-preventable deaths due to tuberculosis, thus an alternative vaccine is required. One of the principal barriers to vaccine development against M. tuberculosis is the complexity of the immune response to infection, with uncertainty as to what constitutes an immunological correlate of protection. In this paper, we seek to give an overview of the immunology of M. tuberculosis infection, and by doing so, investigate possible targets of vaccine development. This encompasses the innate, adaptive, mucosal and humoral immune systems. Though MVA85A did not improve protection compared with BCG alone in a large-scale clinical trial, the correlates of protection this has revealed, in addition to promising results from candidate such as VPM1002, M72/ASO1E and H56:IC31 point to a brighter future in the field of TB vaccine development. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
17. Methods for comparing durability of immune responses between vaccine regimens in early-phase trials.
- Author
-
Westling, Ted, Juraska, Michal, Seaton, Kelly E., Tomaras, Georgia D., Gilbert, Peter B., and Janes, Holly
- Subjects
VACCINE effectiveness ,IMMUNE response ,VACCINES ,AIDS vaccines ,DURABILITY ,INFERENTIAL statistics ,HIV prevention ,STATISTICS ,EXPERIMENTAL design ,CLINICAL trials ,DATA analysis - Abstract
The ability to produce a long-lasting, or durable, immune response is a crucial characteristic of many highly effective vaccines. A goal of early-phase vaccine trials is often to compare the immune response durability of multiple tested vaccine regimens. One parameter for measuring immune response durability is the area under the mean post-peak log immune response profile. In this paper, we compare immune response durability across vaccine regimens within and between two phase I trials of DNA-primed HIV vaccine regimens, HVTN 094 and HVTN 096. We compare four estimators of this durability parameter and the resulting statistical inferences for comparing vaccine regimens. Two of these estimators use the trapezoid rule as an empirical approximation of the area under the marginal log response curve, and the other two estimators are based on linear and nonlinear models for the marginal mean log response. We conduct a simulation study to compare the four estimators, provide guidance on estimator selection, and use the nonlinear marginal mean model to analyze immunogenicity data from the two HIV vaccine trials. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
18. Ebola vaccine regimen generates strong immune response in children and adults in a clinical trial in Sierra Leone
- Subjects
Children -- Diseases ,Ebola virus infections ,Immune response ,Clinical trials ,Vaccines ,Ebola virus ,Virus diseases ,Business, international ,Law ,University of London. London School of Hygiene and Tropical Medicine - Abstract
Johnson & Johnsons two-dose Ebola vaccine regimen is safe, well tolerated and produces a strong immune response in people over the age of one, according to two new papers published [...]
- Published
- 2021
19. Preliminary trial results of Sinovac's COVID-19 vaccine shows induced quick immune response
- Subjects
Sinovac Biotech Ltd. ,Clinical trials ,Vaccines ,Immune response ,COVID-19 ,Biological products industry ,Chemistry - Abstract
M2 PHARMA-November 18, 2020-Preliminary trial results of Sinovac's COVID-19 vaccine shows induced quick immune response (C)2020 M2 COMMUNICATIONS Sinovac Biotech Ltd (Sinovac), a Chinese biopharmaceutical company that focuses on vaccines, [...]
- Published
- 2020
20. Preliminary trial results of Sinovac's COVID-19 vaccine shows induced quick immune response
- Subjects
Sinovac Biotech Ltd. ,Clinical trials ,Vaccines ,Immune response ,COVID-19 ,Biological products industry ,Business - Abstract
M2 EQUITYBITES-November 18, 2020-Preliminary trial results of Sinovac's COVID-19 vaccine shows induced quick immune response (C)2020 M2 COMMUNICATIONS http://www.m2.com Sinovac Biotech Ltd (Sinovac), a Chinese biopharmaceutical company that focuses on [...]
- Published
- 2020
21. JNJ's Ebola vaccine regimen demonstrates robust, durable immune response
- Subjects
Bavarian Nordic A/S ,Johnson & Johnson ,Vaccination ,Immune response ,Vaccines ,Pharmaceutical industry ,Business ,News, opinion and commentary - Abstract
Data from two papers published in The Lancet Infectious Diseases demonstrated that the Johnson & Johnson Ebola vaccine regimen, Zabdeno and Mvabea, generated robust humoral immune responses in adults and [...]
- Published
- 2021
22. Revolutionizing Veterinary Health with Viral Vector-Based Vaccines
- Author
-
Jogi, Harsh Rajeshbhai, Smaraki, Nabaneeta, Rajak, Kaushal Kishor, Yadav, Ajay Kumar, Bhatt, Mukesh, Einstien, Chris, Revathi, Annepu, Thakur, Ravi, Kamothi, Dhaval J., Dedeepya, P. V. S. S., and Savsani, H. H.
- Published
- 2024
- Full Text
- View/download PDF
23. Development of experimental pneumococcal vaccine for mucosal immunization.
- Author
-
Gupalova, Tatiana, Leontieva, Galina, Kramskaya, Tatiana, Grabovskaya, Kornelya, Kuleshevich, Eugenia, and Suvorov, Alexander
- Subjects
STREPTOCOCCUS pneumoniae ,IMMUNIZATION ,PNEUMOCOCCAL vaccines ,ENTEROCOCCUS faecium ,CHIMERIC proteins ,LABORATORY mice - Abstract
Streptococcus pneumonia is an important human pathogen that causes various severe diseases such as pneumonia, otitis and meningitis. Vaccination against S. pneumoniae is implemented in many developed countries. The presently used vaccines are safe, well tolerated but relatively expensive and require modification due to the immunological changes of the epidemic strains. This paper describes the development of a new pneumococcal vaccine candidate for immunization on mucosal surfaces. For this purpose the antigens of chimeric protein PSPF, previously suggested for an injectable S. pneumoniae vaccine, were expressed on the surface of the live probiotic strain Enterococcus faecium L3. Experiments on laboratory mice vaccinated with live bacteria demonstrated the appearance of the specific IgA and IgG which provide protection against the lethal S. pneumoniae infection. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
24. The adjuvant AlhydroGel elicits higher antibody titres than AddaVax when combined with HIV-1 subtype C gp140 from CAP256.
- Author
-
van Diepen, Michiel T., Chapman, Rosamund, Moore, Penny L., Margolin, Emmanuel, Hermanus, Tandile, Morris, Lynn, Ximba, Phindile, Rybicki, Edward P., and Williamson, Anna-Lise
- Subjects
MOLECULAR weights ,MOLECULAR physics ,HIV ,CELLULAR immunity ,FURIN protein - Abstract
With the HIV-1 epidemic in southern Africa still rising, a prophylactic vaccine against the region’s most prolific subtype (subtype C) would be a significant step forward. In this paper we report on the effect of 2 different adjuvants, AddaVax and AlhydroGel, formulated with HIV-1 subtype C gp140, on the development of binding and neutralising antibody titres in rabbits. AddaVax is a squalene-based oil-in-water nano-emulsion (similar to MF59) which can enhance both cellular and humoral immune responses, whilst AlhydroGel (aluminium hydroxide gel) mainly drives a Th2 response. The gp140 gene tested was derived from the superinfecting virus (SU) from participant CAP256 in the CAPRISA 002 Acute infection cohort. The furin cleavage site of the Env protein was replaced with a flexible linker and an I559P mutation introduced. Lectin affinity purified soluble Env protein was mainly trimeric as judged by molecular weight using BN-PAGE and contained intact broadly neutralising epitopes for the V3-glycan supersite (monoclonal antibodies PGT128 and PGT135), the CD4 binding site (VRC01) and the V2-glycan (PG9) but not for the trimer-specific monoclonal antibodies PG16, PGT145 and CAP256-VRC26_08. When this soluble Env protein was tested in rabbits, AlhydroGel significantly enhanced soluble Env and V1V2 binding antibodies when compared to AddaVax. Finally, AlhydroGel resulted in significantly higher neutralization titres for a subtype C Tier 1A virus (MW965.26) and increased neutralization breadth to Tier 1A and 1B viruses. However, no autologous Tier 2 neutralisation was observed. These data suggest that adjuvant selection is critical for developing a successful vaccine and AlhydroGel should be further investigated. Additional purification of trimeric native-like CAP256 Env and/or priming with DNA or MVA might enhance the induction of neutralizing antibodies and possible Tier 2 HIV-1 neutralisation. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
25. Development of a novel S. Typhi and Paratyphi A outer membrane vesicles based bivalent vaccine against enteric fever.
- Author
-
Howlader, Debaki R., Koley, Hemanta, Sinha, Ritam, Maiti, Suhrid, Bhaumik, Ushasi, Mukherjee, Priyadarshini, and Dutta, Shanta
- Subjects
SALMONELLA typhi ,TYPHOID fever ,BACTERIAL vaccines ,IMMUNOGENETICS ,ANTIGENS - Abstract
Salmonella Typhi and Salmonella Paratyphi A are the leading causative agents of enteric fever which cause morbidity and mortality worldwide. Currently, there is no combination vaccine which could protect infection from both the strains. In this paper, we are focusing on the development of a novel bivalent typhoidal Outer Membrane Vesicles (OMVs) based immunogen against enteric fever. We have isolated Salmonella Typhi and Paratyphi A OMVs and also characterized OMVs associated antigens. Then we immunized adult mice with three doses of our newly formulated bivalent immunogen orally (25 μg/200 μl). After three doses of oral immunization, we found our immunogen could significantly induce humoral response. We have also found serum IgG against LPS, Vi-polysaccharide etc. OMV immunization induces CD4, CD8 and CD19 population in immunized mice spleen. It also induces Th1 and Th17-cell mediated immunity. We also found bivalent OMVs immunization can prevent more than lethal dose of heterologous Salmonella strains mediated systemic infection in adult mice model. We determined that, the protective immune responses depend on the humoral and cell-mediated immune response. Furthermore, we have evaluated the mode of protective immune response carried out by anti-OMVs antibody by significantly inhibiting bacterial motility and mucin penetration ability. Taken together, these findings suggest that our bivalent immunogen could be used as a novel candidate vaccine against enteric fever. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
26. Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.
- Author
-
Kumar Rai, Ganesh, Saluja, Tarun, Chaudhary, Shipra, Tamrakar, Dipesh, Kanodia, Piush, Giri, Bishnu Rath, Shrestha, Rajeev, Uranw, Surendra, Kim, Deok Ryun, Yang, Jae Seung, Park, Il-Yeon, Kyung, Seung-Eun, Vemula, Sridhar, Reddy E, Jagadeesh, Kim, Bomi, Gupta, Birendra Prasad, Jo, Sue Kyoung, Ryu, Ji Hwa, Park, Ho Keun, and Shin, Jong Hoon
- Subjects
- *
CLINICAL trials , *IMMUNE response , *TYPHOID fever , *CURRENT good manufacturing practices , *INTRAMUSCULAR injections , *VACCINES , *DPT vaccines , *HUMAN research subjects , *RANDOMIZED controlled trials , *TYPHOID vaccines , *STATISTICAL sampling - Abstract
Background: Typhoid fever is an endemic disease in many low-income and middle-income countries. The 2018 WHO position paper recommends that countries should consider typhoid vaccination in high-risk groups and for outbreak control. To address the typhoid vaccine supply and demand gap, a typhoid Vi polysaccharide-diphtheria toxoid (Vi-DT) conjugate vaccine development effort was undertaken to achieve WHO prequalification and contribute to the global supply of typhoid conjugate vaccine. The main aim of this study was to show immune non-inferiority of the Vi-DT vaccine compared with the WHO prequalified Vi polysaccharide-tetanus toxoid (Vi-TT) conjugate vaccine (Typbar TCV; Bharat Biotech India, Hyderabad, India) in participants of various ages from an endemic country.Methods: We did an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial at four hospitals in Kathmandu, Dhulikhel, Dharan, and Nepalgunj in Nepal. Eligible participants were healthy individuals aged 6 months to 45 years for whom informed consent was obtained, were willing to follow the study procedures and were available for the duration of the study. Patients with an acute or chronic illness that could interfere with interpretation of the study endpoints, or who were involved in any other clinical trial were excluded. Participants were randomly assigned (1:1:1:1) by block randomisation (block size of four and eight), stratified by age (6 months to <2 years, 2 years to <18 years, and 18 years to 45 years), into one of four groups (A-D). Participants in groups A-C received a single dose (25 μg; 0·5 mL) of Vi-DT test vaccine via intramuscular injection from one of three good manufacturing practice lots (group A received lot 1, group B received lot 2, and group C received lot 3), and those in group D received a single dose (25 μg; 0·5 mL) of the Vi-TT vaccine via intramuscular injection. All participants, site staff (except for those who administered the study vaccines), and those assessing the outcomes were masked to group assignment. The co-primary endpoints were: (1) non-inferiority of immunogenicity of the Vi-DT vaccine (pooled groups A-C) versus the Vi-TT vaccine (group D), measured by the anti-Vi IgG seroconversion rate at 4 weeks after vaccination; and (2) the lot-to-lot consistency of the Vi-DT vaccine, measured by immune equivalence of the anti-Vi IgG geometric mean titre (GMT) at 4 weeks after receipt of the three Vi-DT vaccine lots (lot 1 vs lot 2, lot 1 vs lot 3, and lot 2 vs lot 3). Non-inferiority of the Vi-DT vaccine compared with the Vi-TT vaccine was shown if the lower limit of the 97·5% CI for the difference between the seroconversion rates in Vi-DT vaccine groups A-C combined versus Vi-TT vaccine group D was above the predefined non-inferiority margin of -10%. Lot-to-lot immune equivalence was shown if the upper and lower bounds of the two-sided 99·17% CI around the GMT ratio for each pairwise lot-to-lot comparison was between 0·67 and 1·50, which is the predefined equivalence margin recommended by WHO. The co-primary immunogenicity endpoints were assessed in all randomised participants who had received their assigned vaccine and had completed at least one post-baseline immunogenicity assessment. Safety was descriptively summarised by group and age strata, and was assessed in all participants who had received one dose of the investigational vaccine. The trial is registered with ClinicalTrials.gov, NCT03933098.Findings: Between Nov 20, 2019, and March 10, 2020, 1854 individuals were screened, of whom 1800 were enrolled and randomly assigned to groups A-D (450 participants in each group). 1786 (99·2%; 443 in group A, 450 in group B, 447 in group C, and 446 in group D) were included in the immunogenicity assessments at 4 weeks post vaccination, and all 1800 participants were included in the safety analysis. In the immunogenicity analysis, the anti-Vi-IgG seroconversion rate in all age strata was 99·33% (97·5% CI 98·61 to 99·68; 1331 of 1340 participants) in Vi-DT vaccine groups A-C and 98·88% (97·10 to 99·57; 441 of 446) in Vi-TT vaccine group D. The difference in seroconversion rates between Vi-DT vaccine groups A-C combined versus Vi-TT group D was 0·47% (97·5% CI -0·68 to 1·61), indicating non-inferiority of the Vi-DT vaccine. Anti-Vi-IgG GMT ratios at 4 weeks post-vaccination were 1·02 (99·17% CI 0·85 to 1·22) for lot 1 versus lot 2, 1·02 (0·85 to 1·23) for lot 1 versus lot 3, and 1·01 (0·84 to 1·21) for lot 2 versus lot 3, indicating lot-to-lot equivalence according to the predefined, WHO-recommended equivalence margin. The proportion of participants reporting adverse events was similar between Vi-DT vaccine groups A-C and Vi-TT vaccine group D; 260 (19·3%) of 1350 participants in Vi-DT vaccine groups A-C and 115 (25·6%) of 450 in Vi-TT vaccine group D reported solicited adverse events within 7 days after vaccination, and 208 (15·4%) in Vi-DT vaccine groups A-C and 76 (16·9%) in Vi-TT vaccine group D reported unsolicited adverse events within 4 weeks after vaccination. Seven serious adverse events (four [0·3%] participants in Vi-DT vaccine groups A-C and three [0·7%] in Vi-TT vaccine group D), including one death in the Vi-TT vaccine group, were reported during the 24-week follow-up period, none of which were considered related to the investigational product.Interpretation: When administered as a single dose, the Vi-DT test vaccine was safe, immunogenic, and non-inferior to the Vi-TT vaccine at 4 weeks post vaccination. Equivalent immunogenicity of the three lots of Vi-DT vaccine was also shown, supporting the manufacturing process of this vaccine. Once prequalified by WHO, this vaccine could be an option for purchase by UN agencies.Funding: The Bill & Melinda Gates Foundation.Translation: For the Nepali translation of the abstract see Supplementary Materials section. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
27. Liposomes, transfersomes and niosomes: production methods and their applications in the vaccinal field
- Author
-
Domenico Riccardi, Lucia Baldino, and Ernesto Reverchon
- Subjects
Liposomes ,Transfersomes ,Niosomes ,Vaccines ,Immune response ,Antibodies ,Medicine - Abstract
Abstract One of the most effective strategies to fight viruses and handle health diseases is vaccination. Recent studies and current applications are moving on antigen, DNA and RNA-based vaccines to overcome the limitations related to the conventional vaccination strategies, such as low safety, necessity of multiple injection, and side effects. However, due to the instability of pristine antigen, RNA and DNA molecules, the use of nanocarriers is required. Among the different nanocarriers proposed for vaccinal applications, three types of nanovesicles were selected and analysed in this review: liposomes, transfersomes and niosomes. PubMed, Scopus and Google Scholar databases were used for searching recent papers on the most frequently used conventional and innovative methods of production of these nanovesicles. Weaknesses and limitations of conventional methods (i.e., multiple post-processing, solvent residue, batch-mode processes) can be overcome using innovative methods, in particular, the ones assisted by supercritical carbon dioxide. SuperSomes process emerged as a promising production technique of solvent-free nanovesicles, since it can be easily scaled-up, works in continuous-mode, and does not require further post-processing steps to obtain the desired products. As a result of the literature analysis, supercritical carbon dioxide assisted methods attracted a lot of interest for nanovesicles production in the vaccinal field. However, despite their numerous advantages, supercritical processes require further studies for the production of liposomes, transfersomes and niosomes with the aim of reaching well-defined technologies suitable for industrial applications and mass production of vaccines.
- Published
- 2024
- Full Text
- View/download PDF
28. Dried Blood Spots for Measuring Vibrio cholerae-specific Immune Responses.
- Author
-
Iyer, Anita S., Azman, Andrew S., Bouhenia, Malika, Deng, Lul O., Anderson, Cole P., Graves, Michael, Kováč, Pavol, Xu, Peng, Ryan, Edward T., Harris, Jason B., Sack, David A., Luquero, Francisco J., and Leung, Daniel T.
- Subjects
VIBRIO cholerae ,IMMUNE response ,CHOLERA ,DRIED blood spot testing ,BODY fluids ,INFECTIOUS disease transmission - Abstract
Background: Vibrio cholerae causes over 2 million cases of cholera and 90,000 deaths each year. Serosurveillance can be a useful tool for estimating the intensity of cholera transmission and prioritizing populations for cholera control interventions. Current methods involving venous blood draws and downstream specimen storage and transport methods pose logistical challenges in most settings where cholera strikes. To overcome these challenges, we developed methods for determining cholera-specific immune responses from dried blood spots (DBS). Methodology/principal findings: As conventional vibriocidal assay methods were unsuitable for DBS eluates from filter paper, we adopted a drop-plate culture method. We show that DBS collected from volunteers in South Sudan, and stored for prolonged periods in field conditions, retained functional vibriocidal antibodies, the titers of which correlated with paired serum titers determined by conventional spectrophotometric methods (r = 0.94, p = 0.00012). We also showed that eluates from DBS Serum Separator cards could be used with conventional spectrophotometric vibriocidal methods, and that they correlated with paired serum at a wide range of titers (r = 0.96, p<0.0001). Similarly, we used ELISA methods to show that V. cholerae O-specific polysaccharide antibody responses from DBS eluates correlated with results from paired serum for IgG (r = 0.85, p = 0.00006), IgM (r = 0.79, p = 0.00049) and IgA (r = 0.73, p = 0.0019), highlighting its potential for use in determination of isotype-specific responses. Storage of DBS cards at a range of temperatures did not change antibody responses. Conclusion: In conclusion, we have developed and demonstrated a proof-of-concept for assays utilizing DBS for assessing cholera-specific immune responses. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
29. A clinically parameterized mathematical model of Shigella immunity to inform vaccine design.
- Author
-
Davis, Courtney L., Wahid, Rezwanul, Toapanta, Franklin R., Simon, Jakub K., and Sztein, Marcelo B.
- Subjects
HUMORAL immunity ,SHIGELLA ,LIPOPOLYSACCHARIDE structure ,BACTERIAL outer membrane proteins ,BACTERIAL vaccines - Abstract
We refine and clinically parameterize a mathematical model of the humoral immune response against Shigella, a diarrheal bacteria that infects 80-165 million people and kills an estimated 600,000 people worldwide each year. Using Latin hypercube sampling and Monte Carlo simulations for parameter estimation, we fit our model to human immune data from two Shigella EcSf2a-2 vaccine trials and a rechallenge study in which antibody and B-cell responses against Shigella′s lipopolysaccharide (LPS) and O-membrane proteins (OMP) were recorded. The clinically grounded model is used to mathematically investigate which key immune mechanisms and bacterial targets confer immunity against Shigella and to predict which humoral immune components should be elicited to create a protective vaccine against Shigella. The model offers insight into why the EcSf2a-2 vaccine had low efficacy and demonstrates that at a group level a humoral immune response induced by EcSf2a-2 vaccine or wild-type challenge against Shigella′s LPS or OMP does not appear sufficient for protection. That is, the model predicts an uncontrolled infection of gut epithelial cells that is present across all best-fit model parameterizations when fit to EcSf2a-2 vaccine or wild-type challenge data. Using sensitivity analysis, we explore which model parameter values must be altered to prevent the destructive epithelial invasion by Shigella bacteria and identify four key parameter groups as potential vaccine targets or immune correlates: 1) the rate that Shigella migrates into the lamina propria or epithelium, 2) the rate that memory B cells (B
M ) differentiate into antibody-secreting cells (ASC), 3) the rate at which antibodies are produced by activated ASC, and 4) the Shigella-specific BM carrying capacity. This paper underscores the need for a multifaceted approach in ongoing efforts to design an effective Shigella vaccine. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
30. Nanoparticle-based strategies for cancer immunotherapy and immunodiagnostics.
- Author
-
Grimaldi, Anna Maria, Incoronato, Mariarosaria, Salvatore, Marco, and Soricelli, Andrea
- Abstract
Although recent successes in clinical trials are strengthening research focused on cancer immunology, the poor immunogenicity and off-target side effects of immunotherapeutics remain major challenges in translating these promising approaches to clinically feasible therapies in the treatment of a large range of tumors. Nanotechnology offers target-based approaches, which have shown significant improvements in the rapidly advancing field of cancer immunotherapy. Here, we first discuss the chemical and physical features of nanoparticulate systems that can be tuned to address the anticancer immune response, and then review recent, key examples of the exploited strategies, ranging from nanovaccines to NPs revising the tumor immunosuppressive microenvironment, up to immunotherapeutic multimodal NPs. Finally, the paper concludes by identifying the promising and outstanding challenges the field of emerging nanotechnologies is facing for cancer immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
31. Vaccines Induce Homeostatic Immunity, Generating Several Secondary Benefits.
- Author
-
Arunachalam, Arun B.
- Subjects
IMMUNITY ,VACCINES ,IMMUNE response ,IMMUNE system ,AUTOIMMUNE diseases - Abstract
The optimal immune response eliminates invading pathogens, restoring immune equilibrium without inflicting undue harm to the host. However, when a cascade of immunological reactions is triggered, the immune response can sometimes go into overdrive, potentially leading to harmful long-term effects or even death. The immune system is triggered mostly by infections, allergens, or medical interventions such as vaccination. This review examines how these immune triggers differ and why certain infections may dysregulate immune homeostasis, leading to inflammatory or allergic pathology and exacerbation of pre-existing conditions. However, many vaccines generate an optimal immune response and protect against the consequences of pathogen-induced immunological aggressiveness, and from a small number of unrelated pathogens and autoimmune diseases. Here, we propose an "immuno-wave" model describing a vaccine-induced "Goldilocks immunity", which leaves fine imprints of both pro-inflammatory and anti-inflammatory milieus, derived from both the innate and the adaptive arms of the immune system, in the body. The resulting balanced, 'quiet alert' state of the immune system may provide a jump-start in the defense against pathogens and any associated pathological inflammatory or allergic responses, allowing vaccines to go above and beyond their call of duty. In closing, we recommend formally investigating and reaping many of the secondary benefits of vaccines with appropriate clinical studies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
32. Trans-Amplifying RNA: A Journey from Alphavirus Research to Future Vaccines.
- Author
-
Yıldız, Ayşegül, Răileanu, Cristian, and Beissert, Tim
- Subjects
RNA ,VACCINES ,MESSENGER RNA ,CLINICAL medicine ,IMMUNE response - Abstract
Replicating RNA, including self-amplifying RNA (saRNA) and trans-amplifying RNA (taRNA), holds great potential for advancing the next generation of RNA-based vaccines. Unlike in vitro transcribed mRNA found in most current RNA vaccines, saRNA or taRNA can be massively replicated within cells in the presence of RNA-amplifying enzymes known as replicases. We recently demonstrated that this property could enhance immune responses with minimal injected RNA amounts. In saRNA-based vaccines, replicase and antigens are encoded on the same mRNA molecule, resulting in very long RNA sequences, which poses significant challenges in production, delivery, and stability. In taRNA-based vaccines, these challenges can be overcome by splitting the replication system into two parts: one that encodes replicase and the other that encodes a short antigen-encoding RNA called transreplicon. Here, we review the identification and use of transreplicon RNA in alphavirus research, with a focus on the development of novel taRNA technology as a state-of-the art vaccine platform. Additionally, we discuss remaining challenges essential to the clinical application and highlight the potential benefits related to the unique properties of this future vaccine platform. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. The Role of Biological Sex in Pre-Clinical (Mouse) mRNA Vaccine Studies.
- Author
-
Binici, Burcu, Rattray, Zahra, Schroeder, Avi, and Perrie, Yvonne
- Subjects
SEX (Biology) ,MESSENGER RNA ,GENE expression ,INTRAMUSCULAR injections ,VACCINES - Abstract
In this study, we consider the influence of biological sex-specific immune responses on the assessment of mRNA vaccines in pre-clinical murine studies. Recognising the established disparities in immune function attributed to genetic and hormonal differences between individuals of different biological sexes, we compared the mRNA expression and immune responses in mice of both biological sexes after intramuscular injection with mRNA incorporated within lipid nanoparticles. Regarding mRNA expression, no significant difference in protein (luciferase) expression at the injection site was observed between female and male mice following intramuscular administration; however, we found that female BALB/c mice exhibit significantly greater total IgG responses across the concentration range of mRNA lipid nanoparticles (LNPs) in comparison to their male counterparts. This study not only contributes to the scientific understanding of mRNA vaccine evaluation but also emphasizes the importance of considering biological sex in vaccine study designs during pre-clinical evaluation in murine studies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
34. The Host Response to Coccidioidomycosis.
- Author
-
Kirkland, Theo N., Hung, Chiung-Yu, Shubitz, Lisa F., Beyhan, Sinem, and Fierer, Joshua
- Subjects
COCCIDIOIDOMYCOSIS ,NATURAL immunity ,DESERTS ,VACCINE effectiveness ,IMMUNE response - Abstract
Coccidioidomycosis is an important fungal disease that is found in many desert regions of the western hemisphere. The inhaled organisms are highly pathogenic, but only half of infected, immunologically intact people develop symptomatic pneumonia; most symptomatic infections resolve spontaneously, although some resolve very slowly. Furthermore, second infections are very rare and natural immunity after infection is robust. Therefore, the host response to this organism is very effective at resolving the infection in most cases and immunizing to prevent second infections. People who are immunocompromised are much more likely to develop disseminated infection. This is a comprehensive review of the innate and acquired immune responses to Coccidioides spp., the genetics of resistance to severe infection, and the search for an effective vaccine. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
35. Potential of DPD ((S)-4,5-dihydroxy-2,3-pentanedione) Analogs in Microparticulate Formulation as Vaccine Adjuvants.
- Author
-
Joshi, Devyani, Shah, Sarthak, Chbib, Christiane, and Uddin, Mohammad N.
- Subjects
VACCINE immunogenicity ,VACCINES ,DENDRITIC cells ,IMMUNE response ,GONORRHEA - Abstract
The molecule (S)-4,5-dihydroxy-2,3-pentanedione (DPD) is produced by many different species of bacteria and is involved in bacterial communication. DPD is the precursor of signal molecule autoinducer-2 (AI-2) and has high potential to be used as a vaccine adjuvant. Vaccine adjuvants are compounds that enhance the stability and immunogenicity of vaccine antigens, modulate efficacy, and increase the immune response to a particular antigen. Previously, the microparticulate form of (S)-DPD was found to have an adjuvant effect with the gonorrhea vaccine. In this study, we evaluated the immunogenicity and adjuvanticity of several synthetic analogs of the (S)-DPD molecule, including ent—DPD((R)-4,5-dihydroxy-2,3-pentanedione), n-butyl—DPD ((S)-1,2-dihydroxy-3,4-octanedione), isobutyl—DPD ((S)-1,2-dihydroxy-6-methyl-3,4-heptanedione), n-hexyl—DPD ((S)-1,2-dihydroxy-3,4-decanedione), and phenyl—DPD ((S)-3,4-dihydroxy-1-phenyl-1,2-butanedione), in microparticulate formulations. The microparticulate formulations of all analogs of (S)-DPD were found to be noncytotoxic toward dendritic cells. Among these analogs, ent—DPD, n-butyl—DPD, and isobutyl—DPD were found to be immunogenic toward antigens and showed adjuvant efficacy with microparticulate gonorrhea vaccines. It was observed that n-hexyl—DPD and phenyl—DPD did not show any adjuvant effect. This study shows that synthetic analogs of (S)-DPD molecules are capable of eliciting adjuvant effects with vaccines. A future in vivo evaluation will further confirm that these analogs are promising vaccine adjuvants. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. Impact of Antenatal SARS-CoV-2 Exposure on SARS-CoV-2 Neutralization Potency.
- Author
-
Chiang, Chia-Jung, Hsu, Wei-Lun, Su, Mei-Tsz, Ko, Wen-Chien, Hsu, Keng-Fu, and Tsai, Pei-Yin
- Subjects
SARS-CoV-2 Omicron variant ,SARS-CoV-2 ,COVID-19 ,BOOSTER vaccines ,PREGNANT women - Abstract
A pregnancy booster dose significantly reduces the risk and severity of COVID-19, and it is widely recommended. A prospective cohort study was conducted to compare the transplacental passage of maternal antibodies from vaccination or infection during three trimesters against both the vaccine-targeted Wuhan strain and the Omicron strain of SARS-CoV-2. Maternal–infant dyads from vaccinated mothers were collected between 6 June 2022 and 20 September 2022. We analyzed 38 maternal–infant dyads from mothers who had been infected with COVID-19 and 37 from mothers without any previous infection. Pregnant women who received their last COVID-19 vaccine dose in the third trimester exhibited the highest anti-spike protein antibody levels and neutralizing potency against both the Wuhan strain and Omicron BA.2 variant in their maternal and cord plasma. Both second- and third-trimester vaccination could lead to a higher level of neutralization against the Wuhan and Omicron strains. COVID-19 infection had a negative effect on the transplacental transfer ratio of SARS-CoV-2 antibodies. A booster dose during the second or third trimester is encouraged for the maximum transplacental transfer of humoral protection against COVID-19 for infants. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. Assessment of BoAHV-1 Seronegative Latent Carrier by the Administration of Two Infectious Bovine Rhinotracheitis Live Marker Vaccines in Calves.
- Author
-
Petrini, Stefano, Righi, Cecilia, Costantino, Giulia, Scoccia, Eleonora, Gobbi, Paola, Pellegrini, Claudia, Pela, Michela, Giammarioli, Monica, Viola, Giulio, Sabato, Roberto, Tinelli, Elena, and Feliziani, Francesco
- Subjects
CALVES ,VACCINES ,BOS ,INFECTIOUS disease transmission ,IMMUNE response - Abstract
Seronegative latent carriers (SNLCs) are animals that carry the virus without detectable antibodies and pose a risk for disease transmission and diagnostic challenges, suggesting the importance of consideration of marker vaccines in managing them. Therefore, in this study, we evaluated two modified live infectious bovine rhinotracheitis (IBR) marker vaccines (single and double deletions) for their ability to generate SNLC calves. These vaccines were administered to four groups (n = 3 in each group) of three-month-old calves in the presence or absence of passive immunity. Three hundred days after the first vaccination and after confirming the IBR seronegativity of all animals, dexamethasone was administered intravenously for five consecutive days. Only animals immunized with the modified live IBR marker vaccine (single deletion) in the absence of passive immunity exhibited a more enduring immune response than those vaccinated in the presence of passive immunity. Moreover, the administration of a modified live IBR marker vaccine (double deletion) to calves with passive immunity generated SNLC. These findings underscore the potential of live IBR marker vaccine (double-deletions) to aid serological diagnostic tools and develop vaccination protocols in achieving the desired immune response, particularly in the context of latent carrier status, offering valuable insights into optimizing vaccination strategies for effective IBR control. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. A phase II clinical trial of a Vi-DT typhoid conjugate vaccine in healthy Indonesian adolescents and adults: one-month evaluation of safety and immunogenicity.
- Author
-
Koesnoe, Sukamto, Medise, Bernie Endyarni, Rengganis, Iris, Hadinegoro, Sri Rezeki, Puspita, Mita, Sari, Rini Mulia, Yang, Jae Seung, Sahastrabuddhe, Sushant, Soedjatmiko, Gunardi, Hartono, Sekartini, Rini, Wirahmadi, Angga, Kekalih, Aria, Mukhi, Sreshta, Satari, Hindra Irawan, and Bachtiar, Novilia Sjafri
- Subjects
TYPHOID fever ,IMMUNE response ,CLINICAL trials ,VACCINES ,MYALGIA - Abstract
Background: Typhoid fever is commonly found until today, especially in developing countries. It has fatal complications and measures must be taken to reduce the incidence of typhoid. Vaccinations are a key factor in prevention. This is a phase II randomized observer-blind clinical trial on a novel Vi-DT conjugate vaccine on 200 subjects 12 to 40 years of age. Methods: Subjects were screened for eligibility after which a blood sample was taken and one dose of vaccine was administered. Investigational vaccine used was Vi-DT and control was Vi-PS. Twenty-eight days after vaccination, subjects visited for providing blood sample to assess immunogenicity and were asked about local and systemic adverse reactions that occurred in the first 28 days. Results: Subjects had minor adverse reactions. Pain was the most common local reaction. Muscle pain was the most common systemic reaction. There were no serious adverse events up to 28 days post vaccination. Seroconversion rates were 100% in the Vi-DT group and 95.96% in the Vi-PS group. Post vaccination GMTs were increased in both groups but it was significantly higher in the Vi-DT group (p < 0.001). Conclusions: Vi-DT typhoid conjugate vaccine is safe and immunogenic in healthy Indonesian subjects 12 to 40 years. Trial registration: Approved by ClinicalTrials.gov. Clinical trial registration number: NCT03460405. Registered on 09/03/2018. URL: https://clinicaltrials.gov/ct2/show/NCT03460405. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. Plasmodium vivax cell-Traversal Protein for Ookinetes and Sporozoites: Naturally Acquired Humoral Immune Response and B-Cell Epitope Mapping in Brazilian Amazon Inhabitants.
- Author
-
Nunes Rodrigues-da-Silva, Rodrigo, Ferreira Soares, Isabela, Lopez-Camacho, Cesar, Martins da Silva, João Hermínio, de Souza Perce-da-Silva, Daiana, Têva, Antônio, Ramos Franco, Antônia Maria, Gomes Pinheiro, Francimeire, Bitencourt Chaves, Lana, Pratt-Riccio, Lilian Rose, Reyes-Sandoval, Arturo, Banic, Dalma Maria, and da Costa Lima-Junior, Josué
- Subjects
PLASMODIUM vivax ,PROTOZOAN proteins ,IMMUNE response - Abstract
The cell-traversal protein for ookinetes and sporozoites (CelTOS), a highly conserved antigen involved in sporozoite motility, plays an important role in the traversal of host cells during the preerythrocytic stage of Plasmodium species. Recently, it has been considered an alternative target when designing novel antimalarial vaccines against Plasmodium falciparum. However, the potential of Plasmodium vivax CelTOS as a vaccine target is yet to be explored. This study evaluated the naturally acquired immune response against a recombinant P. vivax CelTOS (PvCelTOS) (IgG and IgG subclass) in 528 individuals from Brazilian Amazon, as well as the screening of B-cell epitopes in silico and peptide assays to associate the breadth of antibody responses of those individuals with exposition and/or protection correlates. We show that PvCelTOS is naturally immunogenic in Amazon inhabitants with 94 individuals (17.8%) showing specific IgG antibodies against the recombinant protein. Among responders, the IgG reactivity indexes (RIs) presented a direct correlation with the number of previous malaria episodes (p = 0.003; r = 0.315) and inverse correlation with the time elapsed from the last malaria episode (p = 0.031; r = -0.258). Interestingly, high responders to PvCelTOS (RI > 2) presented higher number of previous malaria episodes, frequency of recent malaria episodes, and ratio of cytophilic/ non-cytophilic antibodies than low responders (RI < 2) and non-responders (RI < 1). Moreover, a high prevalence of the cytophilic antibody IgG1 over all other IgG subclasses (p < 0.0001) was observed. B-cell epitope mapping revealed five immunogenic regions in PvCelTOS, but no associations between the specific IgG response to peptides and exposure/protection parameters were found. However, the epitope (PvCelTOSI136-E143) was validated as a main linear B-cell epitope, as 92% of IgG responders to PvCelTOS were also responders to this peptide sequence. This study describes for the first time the natural immunogenicity of PvCelTOS in Amazon individuals and identifies immunogenic regions in a full-length protein. The IgG magnitude was mainly composed of cytophilic antibodies (IgG1) and associated with recent malaria episodes. The data presented in this paper add further evidence to consider PvCelTOS as a vaccine candidate. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
40. Gaining ground on a cure through synergy: combining checkpoint inhibitors with cancer vaccines.
- Author
-
Vreeland, T. J., Clifton, G. T., Herbert, G. S., Hale, D. F., Jackson, D. O., Berry, J. S., and Peoples, G. E.
- Subjects
CANCER vaccines ,IMMUNOTHERAPY ,DENDRITIC cells ,HEALTH of cancer patients ,TUMOR microenvironment ,LYMPHOCYTES ,IMMUNE response ,EQUIPMENT & supplies ,TUMORS ,DISEASES ,VACCINES - Abstract
Introduction: The approval of multiple checkpoint inhibitors (CPIs) for the treatment of advanced malignancies has sparked an explosion of research in the field of cancer immunotherapy. Despite the success of these medications, a large number of patients with advanced malignancy do not benefit from therapy. Early research indicates that a therapeutic combination of cancer vaccines with checkpoint inhibitors may lead to synergistic effects and higher response rates than monotherapy. Areascovered: This paper summarizes the previously completed and ongoing research on this exciting combination, including the use of the tumor lysate, particle-loaded dendritic cell (TLPLDC) vaccine combined with checkpoint inhibitors in advanced melanoma. Expertcommentary: Increasing experience with CPIs has led to improved understanding of which patients may benefit and it is increasingly clear that the presence of a pre-existing immune response to the tumor, along with tumor-infiltrating lymphocytes, is key to the success of CPIs. One exciting possibility for the future is the addition of a cancer vaccine to CPI therapy, eliciting these crucial T cells, which can then be augmented and protected by the CPI. A number of current and future studies are addressing this very exciting combination therapy. [ABSTRACT FROM PUBLISHER]
- Published
- 2016
- Full Text
- View/download PDF
41. Mycobacterium ulcerans Mouse Model Refinement for Pre-Clinical Profiling of Vaccine Candidates.
- Author
-
Bénard, Angèle, Sala, Claudia, and Pluschke, Gerd
- Subjects
MYCOBACTERIUM ,BURULI ulcer ,TROPICAL medicine ,MACROPHAGES ,TREATMENT effectiveness ,LABORATORY mice - Abstract
Buruli Ulcer is a neglected tropical disease leading to extensive disabilities and morbidity in West Africa. In this paper we sought to characterize various strains of Mycobacterium ulcerans (M.ulcerans) with different origins and laboratory passage records while refining a mouse model for Buruli ulcer. We described, compared and followed the kinetics of the histo-pathological outcome of infection of a collection of strains at various anatomical sites of infection in order to find a suitable model for further immunization studies. Moreover we compared the outcome of infection in C57Bl/6 and Balbc/J mice. Specifically we described thoroughly one M. ulcerans strain characterized by slow growth rate and limited tissue necrosis, which presents close ressemblance with the infection kinetics in humans. This strain caused macrophages as well as T and B cells infiltration, correlating with mycobacterial proliferation at the site of infection as well as in the draining lymph nodes, making it a suitable strain to screen vaccine candidates efficacy. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
42. Immunogenicity of Recombinant Lipid-Based Nanoparticle Vaccines: Danger Signal vs. Helping Hand.
- Author
-
Temchura, Vladimir, Wagner, Jannik T., and Damm, Dominik
- Subjects
IMMUNE response ,NANOPARTICLES ,CELLULAR immunity ,VACCINES ,VACCINE development ,BIOMOLECULES - Abstract
Infectious diseases are a predominant problem in human health. While the incidence of many pathogenic infections is controlled by vaccines, some pathogens still pose a challenging task for vaccine researchers. In order to face these challenges, the field of vaccine development has changed tremendously over the last few years. For non-replicating recombinant antigens, novel vaccine delivery systems that attempt to increase the immunogenicity by mimicking structural properties of pathogens are already approved for clinical applications. Lipid-based nanoparticles (LbNPs) of different natures are vesicles made of lipid layers with aqueous cavities, which may carry antigens and other biomolecules either displayed on the surface or encapsulated in the cavity. However, the efficacy profile of recombinant LbNP vaccines is not as high as that of live-attenuated ones. This review gives a compendious picture of two approaches that affect the immunogenicity of recombinant LbNP vaccines: (i) the incorporation of immunostimulatory agents and (ii) the utilization of pre-existing or promiscuous cellular immunity, which might be beneficial for the development of tailored prophylactic and therapeutic LbNP vaccine candidates. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
43. PCV13, PCV15 or PCV20: Which vaccine is best for children in terms of immunogenicity?
- Author
-
De Wals, Philippe
- Subjects
IMMUNE response ,VACCINE immunogenicity ,PNEUMOCOCCAL vaccines ,VACCINES ,TODDLERS - Abstract
Background: The new 15 and 20-valent pneumococcal conjugate vaccines (PCV15 and PCV20) have been marketed on the basis of immunogenicity criteria, one of them being a non-inferior response as compared with the 13-valent vaccine (PCV13). In the past, PCV13 was also authorized on the basis of the same criteria, using the 7-valent vaccine (PCV7) as a reference. Methods: Our aim was to compare the immunogenicity of these three vaccines in toddlers. Functional opsonophagocytotic activity (OPA) titre ratios measured in the same and different randomized trials were computed to assess the respective immunogenicity of these four products. Results: Results suggest that both PCV15 and PCV20 are less immunogenic than PCV13 for most common serotypes and that the two new vaccines induce a broadly similar response. The PCV7 vaccine was already slightly more immunogenic than PCV13 meaning that PCV15 and PCV20 compare poorly with PCV7. Results also point towards a reduced immunogenicity of the 2+1 dose schedule compared to the 3+1 dose schedule for PCV13, PCV15 and PCV20. Conclusion: Post-marketing studies will have to be conducted to assess the effectiveness of PCV15 and PCV20 and their real-life benefit over PCV13. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
44. Analysis of seroconversion following COVID-19 vaccination among multiple sclerosis patients treated with disease--modifying therapies in Poland.
- Author
-
Podlecka-Piętowska, Aleksandra, Sierdziński, Janusz, Nojszewska, Monika, Stawicki, Jakub, Bartosik-Psujek, Halina, Lech, Beata, Popiel, Małgorzata, Perenc, Adam, Kułakowska, Alina, Czarnowska, Agata, Kulikowska, Joanna, Kapica-Topczewska, Katarzyna, Jamroz-Wiśniewska, Anna, Rejdak, Konrad, Zaborski, Jacek, Kubicka-Bączyk, Katarzyna, Niedziela, Natalia, Wierzbicki, Krzysztof, Adamczyk-Sowa, Monika, and Zwiernik, Jacek
- Abstract
Clinical rationale for the study. The rapid spread of SARS-CoV-2 throughout the world has highlighted the importance of vaccinations to control the pandemic and to protect people at risk for severe disease courses. Disease-modifying therapies (DMT) in multiple sclerosis (MS), whether immunomodulatory or immunosuppressive, may affect the immune response. Therefore, the question arose as to whether these vaccinations would be effective. Aim of the study. We planned a study to assess the immune response to SARS-CoV-2 vaccines by type of therapy. Material and methods. Participants were recruited from 14 Polish MS centres. The data was obtained by neurologists using a questionnaire. We collected data on 353 MS patients (269 females, 84 males) who received complete primary SARS-CoV-2 vaccination. All persons with MS (PwMS) were treated with disease-modifying therapies. Results. 305 out of 353 PwMS (86.4%) were positive for IgG Abs against SARS-CoV-2 S domain S1 Ag after vaccination. A strong immune response was noted in 129 PwMS (36.5%). The rate of seroconversion after SARS-CoV-2 vaccination in PwMS who received immunomodulatory DMTs (interferon beta, glatiramer acetate, teriflunomide, dimethyl fumarate, natalizumab) was 91.5%, in PwMS receiving immune reconstruction therapy (alemtuzumab, cladribine) was 92%, and in immunosuppressive DMTs (fingolimod, ocrelizumab), the seroconversion rate was 59%. Conclusions and clinical implications. Our study shows that, in PwMS receiving immunomodulatory therapy, the immune response to vaccination is generally excellent. Even in immunosuppressive patients, seroconversion is satisfactory. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
45. Immune Response Profiling of Cocktails of Brugia malayi Vaccine Candidates DIM-1, Calponin and Troponin 1 in BALB/c Mice.
- Author
-
Murthy, Puvvada Kalpana, Tewari, Prachi, Mandal, Payal, and Kushwaha, Vikas
- Subjects
IMMUNE response ,TROPONIN I ,COCKTAILS ,IMMUNOGLOBULIN E ,MICE ,VACCINES - Abstract
Purpose: In search of a vaccine for the control of human lymphatic filariasis (LF) caused by Wuchereria bancrofti, Brugia malayi and B. timori, we identified three parasite-specific potential candidates: the disorganized muscle protein-1 (D), calponin (C) and troponin 1 (T) in B. malayi adult worm. In the present study, we investigated the immune response profile of the cocktails of the recombinant D, T and C proteins. Methods: Groups of BALB/c mice were immunized with individual rproteins or their cocktails DT, TC, DC and DTC, and the immunogen-specific IgG and its subclasses and IgE were determined. Cells from the immunized animals were challenged in vitro with the respective rproteins and cocktails and the release of nitric oxide (NO) from macrophages and Th1 and Th2 cytokines from splenocytes were determined. Results: Among the immunized groups, DTC elicited comparatively a stronger response which included augmented release of NO, Th1 (IL-1β, IL-2, IFN-γ and TNF-α) and Th2 (IL-4, IL-6, IL-10 and TGF-β) cytokines, and increased levels of immunogen-specific IgG, IgG1 and IgG2b and low levels of immunogen-specific IgG2a and IgE and the Th2 cytokine IL-13. Conclusion: Immune responses that play important role in host protection were elicited strongly by DTC cocktail compared to the individual rproteins or DT, TC and DC cocktails. The findings provide a sound rationale for further studies on DTC cocktail as a vaccine candidate for the control of LF. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
46. Tumor-derived autophagosome vaccines combined with immune adjuvants mediate antitumor immune responses via the neoantigen pathway.
- Author
-
Jia YUAN, Yue CHANG, Yalan DAI, Yutong CHEN, Rongbin YUE, and Linjuan ZENG
- Subjects
IMMUNOLOGICAL adjuvants ,IMMUNE response ,CANCER vaccines ,TUMOR antigens ,VACCINES ,EXPERIMENTAL arthritis - Abstract
Vaccines composed of autophagosomes derived from tumor cells called DRibbles (DRiPs-containing blebs) are involved in the cross-presentation of tumor antigens, thus inducing cross-reactive T-cell responses against the tumor. Compared with traditional tumor lysate vaccines, autophagosome vaccines were found to be better sources of multiple tumor-associated antigens (TAAs) that activate antigen-specific T-cells. However, the involvement of tumor neoantigens in the immune responses of autophagosome vaccines remains unclear. The present study showed that exogenous autophagosome vaccines (DRibbles) combined with immune adjuvants (anti-OX40 antibody and ATP) can effectively activate functional T cells in vitro. Importantly, the combination of exogenous tumor-derived autophagosome vaccines and immune adjuvants was found to induce tumor regression in B16F10 and 4T1 tumor-bearing mice. The combination of autophagosome-enriched DRibbles with anti-OX40 antibody and ATP also exhibited optimal immune stimulation and antitumor efficiency in vivo. The effectiveness of exogenous DRibble vaccines was mainly due to their enhancement of tumor immunogenicity by increasing the presentation and release of tumor neoantigens. These findings suggest that this immunotherapeutic method may be effective in the treatment of cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
47. Relationships between Parameters for Natural Antibodies, General Immunoglobulins, and Immunocompetent Blood Cells in Sheep in Postvaccination Immune Response
- Author
-
Ezdakova, I. Yu., Kapustina, O. V., Grigoriev, A. G., and Kovaikina, V. M.
- Published
- 2023
- Full Text
- View/download PDF
48. EIGHT MONTHS LATER: RESEARCHERS COMPARE IMMUNE RESPONSES ELICITED BY THREE COVID-19 VACCINES
- Subjects
Pfizer Inc. ,Medical research ,Medicine, Experimental ,Medical centers ,Immune response ,RNA ,Vaccines ,Pharmaceutical industry ,News, opinion and commentary ,Beth Israel Deaconess Medical Center ,Comirnaty (Vaccine) - Abstract
BOSTON, MA -- The following information was released by Beth Israel Deaconess Medical Center (BIDMC): Written by: Jacqueline Mitchell Contact: Chloe Meck, cmeck@bilh.org OCTOBER 15, 2021 Strong antibody response to [...]
- Published
- 2021
49. T-cell 'training grounds' behind robust immune system response seen in adenovirus vaccines
- Subjects
T cells ,Immune system ,Immune response ,Vaccines ,Adenoviruses ,Business, international ,University of Oxford - Abstract
London: University of Oxford has issued the following news release: Adenovirus vaccine vectors, such as the ChAdOx1 nCov-19 construct which has risen to prominence as a major vaccine for COVID-19, [...]
- Published
- 2021
50. Mixed Oxford|Pfizer vaccine schedules generate robust immune response against COVID-19
- Subjects
Pfizer Inc. ,AstraZeneca PLC ,Vaccination ,Immune response ,Vaccines ,Pharmaceutical industry ,Business, international ,Law - Abstract
Alternating doses of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against COVID-19, according to research in which UCLH played a key role. In a paper published on the [...]
- Published
- 2021
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.